ABUS News and Press, Arbutus Biopharma Corporation From 04/18/24

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it...

2024-04-10 04:22:17 ET Summary Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential total win against Moderna, but uncertainties remain regarding the lawsuit and Arbutu...

2024-04-05 14:35:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience...

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the follow...

2024-04-03 12:27:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M Arbutus Biopharma gains after Markman hearing on Thursday in...

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigat...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...

2024-02-09 14:05:35 ET More on Arbutus Biopharma Arbutus Biopharma reports 2023 cash position of ~$132M as of Dec. 31, 2023 Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbut...

2024-02-08 17:13:43 ET Gainers: Farmer Brothers  ( FARM ) +15% . Corvus Pharmaceuticals  ( CRVS ) +10% . Impinj ( PI ) +9% . CalAmp ( CAMP ) +6% . Arbutus Biopharma Corporation ( ABUS ) +6% . Losers: Affirm Hold...